15.12.2010 • News

Hadasit Bio-Holdings is an Investment Interest for Sanofi-Aventis

French drugmaker Sanofi-Aventis is in talks to invest in Hadasit Bio-Holdings, the Israeli biotech holding company said on Tuesday.

Hadasit said the potential investment would be in its KHAR Medical unit, but that no deal had yet been reached. It noted that it was responding to a report in Israel's Calcalist newspaper.

Hadasit, the technology transfer company of Jerusalem's Hadassah University Hospital, said the deal could be thwarted by the disclosure of the talks in the newspaper.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.